XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurement (Tables)
6 Months Ended
Jun. 30, 2022
Summary of Financial Items Carried at Fair Value
Financial items carried at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 are classified in the tables below in one of the three categories of fair value levels:
 
    
June 30, 2022
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
    
(U.S. $ in millions)
 
Cash and cash equivalents:
                                   
Money markets
   $ 451      $ —        $ —        $ 451  
Cash, deposits and other
     1,607        —          —          1,607  
Investment in securities:
                                   
Equity securities
     10        —          —          10  
Other
     5        —          1        6  
Restricted cash
     33        —          —          33  
Derivatives:
                                   
Asset derivatives—options and forward contracts
     —          69        —          69  
Liability derivatives:
                                   
Options and forward contracts
     —          (37      —          (37
Bifurcated embedded derivatives
     —          —          §        —    
Contingent consideration*
     —          —          (205      (205
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 2,106      $ 32      $ (204    $ 1,934  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31, 2021
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
    
(U.S. $ in millions)
 
Cash and cash equivalents:
                                   
Money markets
   $ 220      $ —        $ —        $ 220  
Cash, deposits and other
     1,945        —          —          1,945  
Investment in securities:
                                   
Equity securities
     18        —          —          18  
Other
     6        —          1        7  
Restricted cash
     33        —          —          33  
Derivatives:
                                   
Asset derivatives—options and forward contracts
     —          30        —          30  
Liability derivatives:
                                   
Options and forward contracts
     —          (23      —          (23
Bifurcated embedded derivatives
     —          —          §        —    
Contingent consideration*
   $ —          —          (176      (176
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
     2,222      $ 7      $ (175    $ 2,054  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
§
Represents an amount less than $0.5 million.
*
Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.
Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs:
 
  
Six months
ended June 30,
2022
 
  
Six months
ended
June 30,
2021
 
 
  
(U.S. $ in millions)
 
Fair value at the beginning of the period
   $ (175      (258
Redemption of debt securities
     —          (9
Bifurcated embedded derivatives
     §        —    
Adjustments to provisions for contingent consideration:
                 
Actavis Generics transaction
     (92      22  
Eagle transaction
     (2      (7
Settlement of contingent consideration:
                 
Actavis Generics transaction
     30        —    
Eagle transaction
     46        48  
Additional contingent consideration resulting from Novetide acquisition*
     (11      —    
    
 
 
    
 
 
 
Fair value at the end of the period
   $ (204    $ (204
    
 
 
    
 
 
 
§
Represents an amount less than $0.5 million.
*
In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated
companies.” This
 transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under “Share in (profits) losses of associated companies, net”, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition.
Summary of Financial Instrument Measured on a Basis Other Than Fair Value
Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs):
 
    
Estimated fair value*
 
    
June 30,
    
December 31,
 
    
2022
    
2021
 
    
(U.S. $ in millions)
 
Senior notes and sustainability-linked senior notes included under senior notes and loans
   $ 17,481      $ 21,477  
Senior notes and convertible senior debentures included under short-term debt
     1,702        1,426  
    
 
 
    
 
 
 
Total
   $ 19,183      $ 22,903  
    
 
 
    
 
 
 
 
*
The fair value was estimated based on quoted market prices.